Lifecore Biomedical Announces Sale of Curation Foods’ O Olive Oil and Vinegar® Business
Lifecore Biomedical has announced the successful sale of its O Olive Oil and Vinegar business for $6.23 million, marking the completion of its monetization of remaining Curation Foods assets. The deal includes $3.12 million in cash and a $3.12 million seller's note maturing on March 31, 2026, accruing 12% interest. The O Olive business generated $9.2 million in revenue over the trailing twelve months ending November 27, 2022. Proceeds from the sale will be used to repay existing borrowings under credit facilities, and results from O Olive will be reported as discontinued operations starting fiscal Q4 2023. CEO James G. Hall emphasized the company's focus on long-term growth strategies to meet customer demand.
- Successful sale of O Olive business for $6.23 million.
- Proceeds to be used for debt repayment, strengthening financial position.
- Completion of asset monetization allows focus on core business growth.
- O Olive business generated $9.2 million in revenue, indicating a significant asset disposal.
- Transition to discontinued operations may reflect ongoing restructuring challenges.
CHASKA, Minn., April 06, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has completed the sale of all of its Curation Foods’ assets related to the O Olive Oil and Vinegar® business (“O Olive”) for
James G. Hall, President and Chief Executive Officer of Lifecore, said, “We are pleased to announce the sale of the O Olive Business, which completes our monetization of the remaining Curation Foods assets. Going forward, our team is completely focused on Lifecore and ensuring that we have the financial tools available to execute on our long-term growth strategy to meet customer demand within our development portfolio.”
The O Olive business produces a line of specialty olive oils and vinegars using fresh, California-sourced ingredients. O Olive represented revenue of
The aggregate value of the transaction is
About Lifecore Biomedical
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Lifecore’s website at www.lifecore.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the timing and expenses associated with operations, the ability of the Company to recognize the anticipated benefits of the sale of the O Olive business, future liabilities that may arise from the transaction, including from indemnification or retained assets, litigation that may arise from the transaction, the ability for the purchaser to repay the seller’s note by its terms, or at all, the ability of the Company to continue as a going concern, the timing and expenses associated with operations, and uncertainties related to COVID-19 and the impact of our responses to it. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in our most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
Lifecore Biomedical Contact Information:
Investor Relations
Jeff Sonnek
(646) 277-1263
jeff.sonnek@icrinc.com
FAQ
What is the sale price of Lifecore's O Olive business?
How much revenue did the O Olive business generate?
What will Lifecore do with the proceeds from the sale of O Olive?
When will the results of O Olive business be reported as discontinued operations?
What are the terms of the seller’s note in the sale of O Olive?
